Evonik makes five generations healthier with EUDRAGIT coatings for targeted drug delivery
More than 10,000 scientific publications containing EUDRAGIT
More than 10,000 scientific publications containing EUDRAGIT
This expanded partnership helps Evonik to streamline its distribution model in Asia Pacific
Investment in new plant meets increasing demand for functional excipients for oral drug delivery
Seamless transition from preclinical to first-in-human trials with EUDRACAP platform technology
Supports development and commercialization of complex oral drugs using sensitive molecules, including biologicals
The new structure further transitions the Health Care business line into a system solutions partner for the pharmaceutical and biotech industries
Subscribe To Our Newsletter & Stay Updated